CVS Health Maintains Strong Valuation Despite Share Price Decline
CVS Health (NYSE: CVS) reported strong second-quarter results, with revenue rising 7.3% year-over-year to $106.1 billion and earnings per share increasing by 188%. The company raised its full-year guidance for both revenue and EPS in 2026, signaling continued growth expectations. Despite these positive financials, the stock has declined over 12% in a month due to concerns about future margin pressures. These include membership declines at Caremark by 2027 and ongoing challenges with the 340B drug pricing program. Regulatory scrutiny of its pharmacy benefit manager (PBM) segment is also weighing on investor sentiment. Analysts remain optimistic, setting an average price target nearly 25% above current levels. CVS's vertically integrated business model across retail pharmacies, PBMs, and health insurance gives it a unique position in the healthcare sector with limited direct competition.
Tickers: $CVS
Topics: healthcare insurance pharmaceuticals retail pharmacy